Acquisition Channel Leverage Stryker's global Neurovascular sales and distribution network to rapidly introduce Cerus Endovascular intra-saccular devices to hospitals treating intracranial aneurysms, accelerating market adoption and reach.

Regulatory Pathways Cerus Endovascular has demonstrated FDA clearance for its microcatheters; with Stryker's regulatory and clinical support there is an opportunity to broaden clearances and expand indications faster than solo efforts.

Portfolio Fit Cerus Endovascular's innovative intra-saccular devices complement Stryker's Neurovascular portfolio, enabling cross-sell opportunities to existing customers and potential bundled solutions for aneurysm treatment with integrated support.

Hospital Targeting The lean development and commercial team can benefit from Stryker's enterprise sales approach to target high-volume neurointerventional centers, offering bundled equipment, training, and service packages to boost uptake.

Growth Potential Though current revenue is modest, backing by Stryker's manufacturing scale and capital can unlock volume growth, expanded geographic reach, and accelerated product development through clinical collaboration.